Cullinan Associates Inc Abb Vie Inc. Transaction History

Cullinan Associates Inc

$1.81 Billion
Q3 2024

A detailed history of Cullinan Associates Inc transactions in Abb Vie Inc. stock. As of the latest transaction made, Cullinan Associates Inc holds 109,402 shares of ABBV stock, worth $19.7 Million. This represents 1.2% of its overall portfolio holdings.

Number of Shares

109,402

Previous 120,608 9.29%

Holding current value

$19.7 Million

Previous $20.7 Million 4.44%

% of portfolio

1.2%

Previous 1.18%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 23, 2024	SELL	$163.84 - $199.33 $1.84 Million - $2.23 Million	-11,206 Reduced 9.29%	109,402 $21.6 Million
Q2 2024 Jul 10, 2024	SELL	$154.79 - $180.76 $1.01 Million - $1.18 Million	-6,508 Reduced 5.12%	120,608 $20.7 Million
Q1 2024 Apr 18, 2024	SELL	$159.82 - $182.1 $526,606 - $600,019	-3,295 Reduced 2.53%	127,116 $23.1 Million
Q4 2023 Jan 24, 2024	SELL	$137.6 - $154.97 $2.85 Million - $3.2 Million	-20,680 Reduced 13.69%	130,411 $20.2 Million
Q3 2023 Oct 11, 2023	BUY	$133.59 - $154.65 $1.77 Million - $2.05 Million	13,226 Added 9.59%	151,091 $22.5 Million
Q2 2023 Jul 14, 2023	BUY	$132.51 - $164.9 $697,135 - $867,538	5,261 Added 3.97%	137,865 $18.6 Million
Q1 2023 Apr 05, 2023	BUY	$144.61 - $166.54 $1.02 Million - $1.18 Million	7,080 Added 5.64%	132,604 $21.1 Million
Q4 2022 Jan 11, 2023	BUY	$138.31 - $165.87 $545,909 - $654,688	3,947 Added 3.25%	125,524 $20.3 Million
Q3 2022 Oct 19, 2022	SELL	$134.21 - $153.93 $498,455 - $571,696	-3,714 Reduced 2.96%	121,577 $16.3 Million
Q2 2022 Jul 08, 2022	BUY	$137.62 - $174.96 $1.12 Million - $1.43 Million	8,145 Added 6.95%	125,291 $19.2 Million
Q1 2022 Apr 21, 2022	SELL	$131.98 - $163.75 $1.36 Million - $1.69 Million	-10,297 Reduced 8.08%	117,146 $19 Million
Q4 2021 Jan 07, 2022	BUY	$107.43 - $135.93 $3.96 Million - $5.01 Million	36,841 Added 40.66%	127,443 $17.3 Million
Q3 2021 Oct 08, 2021	BUY	$106.4 - $120.78 $1.31 Million - $1.49 Million	12,353 Added 15.79%	90,602 $9.77 Million
Q2 2021 Jul 07, 2021	BUY	$105.21 - $117.21 $2.5 Million - $2.78 Million	23,757 Added 43.6%	78,249 $8.81 Million
Q1 2021 Apr 20, 2021	BUY	$102.3 - $112.62 $4.16 Million - $4.58 Million	40,661 Added 293.98%	54,492 $5.9 Million
Q4 2020 Jan 14, 2021	BUY	$80.49 - $108.67 $539,283 - $728,089	6,700 Added 93.96%	13,831 $1.48 Million
Q3 2020 Oct 09, 2020	SELL	$85.91 - $100.83 $154,638 - $181,494	-1,800 Reduced 20.15%	7,131 $625,000
Q2 2020 Jul 07, 2020	BUY	$73.37 - $98.18 $149,014 - $199,403	2,031 Added 29.43%	8,931 $877,000
Q1 2020 Apr 01, 2020	SELL	$64.5 - $97.79 $309,600 - $469,392	-4,800 Reduced 41.03%	6,900 $526,000
Q4 2019 Jan 15, 2020	SELL	$72.13 - $90.25 $28,852 - $36,100	-400 Reduced 3.31%	11,700 $1.04 Million
Q3 2019 Oct 01, 2019	BUY	$62.98 - $75.72 $119,662 - $143,868	1,900 Added 18.63%	12,100 $916,000
Q2 2019 Jul 16, 2019	SELL	$65.7 - $83.98 $85,410 - $109,174	-1,300 Reduced 11.3%	10,200 $742,000
Q1 2019 Apr 30, 2019	BUY	$77.14 - $90.79 $256,876 - $302,330	3,330 Added 40.76%	11,500 $927,000
Q3 2018 Oct 19, 2018	SELL	$88.91 - $98.84 $142,256 - $158,144	-1,600 Reduced 16.38%	8,170 $773,000
Q2 2018 Jul 09, 2018	BUY	$89.78 - $106.23 $26,934 - $31,869	300 Added 3.17%	9,770 $905,000
Q1 2018 Apr 27, 2018	BUY	$92.01 - $123.21 $230,025 - $308,025	2,500 Added 35.87%	9,470 $896,000
Q4 2017 Jan 17, 2018	SELL	$89.56 - $98.21 $1.32 Million - $1.44 Million	-14,700 Reduced 67.84%	6,970 $674,000
Q3 2017 Oct 16, 2017	BUY	$69.85 - $89.22 $1.51 Million - $1.93 Million	21,670	21,670 $1.93 Million

Others Institutions Holding ABBV

# of Institutions

3,853

Shares Held

1.25B

Call Options Held

16.8M

Put Options Held

12.2M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cullinan Associates Inc, based on Form 13F filings with the SEC.

News

Stay updated on Cullinan Associates Inc with notifications on news.

Account

Cullinan Associates Inc Abb Vie Inc. Transaction History